THE ONCOALERT NETWORK
  • Home
  • Who are we?
  • OncoAlert🚨Colloquium
  • 🎙️PODCAST
  • VJ OncoAlert Journal Club
  • Oncology📰Monthly
    • Lung Cancer
    • Breast Cancer
    • GU Cancers
  • Multidisciplinary Perspectives in Breast Cancer
  • ASCO 2025
Picture

Oncology Here & NOW

The top topics in oncology, delivered every 10 days by a diverse and highly specialized team of oncologists and urologists from around the world.
The Oncoalert Team brings you relevant and concise 10-minute episodes, three times a month, every month.

Hosts:

  • Dr. Nina Sanford (GI Radiation Oncologist, USA)
  • Dr. Elisa Agostinetto (Breast Oncology, Belgium)
  • Dr. Biagio Ricciuti (Thoracic Oncology, USA)
  • Dr. Joseph McCollom (GI & Geriatric Oncology, USA)
  • Dr. Benedikt Westphalen (GI Med Onc, Germany)
  • Dr. Barbara Melão (Urology, Brazil)
  • Dr. Gil Morgan (Clinical Oncology, USA)


​subscribe👇👇

APPLE Podcasts
AMAZON 
Podcasts
SPOTIFY Podcasts

Treatment of Upper Tract Urothelial Carcinoma with Dr. Melão and Dr. Spiess (May 20, 2025)

Join our Urology colleagues, Dr. Melao and Dr. Spiess, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. They’ll also explore long-term renal function outcomes, a topic on which Dr. Spiess has recently published.

The Annual Report to the Nation on the Status of Cancer with Dr. Jemal and Dr. Morgan (April 28, 2025)

Join Dr. Jemal & Dr Morgan as they discuss this report, a collaboration among major U.S. cancer surveillance organizations, presents the latest national data on cancer incidence and mortality. Using data from cancer registries and national vital statistics, the analysis shows that while overall cancer death rates have steadily declined over the past 20 years — including during the COVID-19 pandemic — the annual rate of decline has recently slowed. Cancer incidence rates remained stable among males and rose slightly among females over time, with a temporary dip across all groups in 2020 likely due to pandemic-related disruptions in healthcare access. However, incidence rates rebounded to prepandemic levels by 2021, suggesting a limited long-term impact of COVID-19 on cancer detection trends.

First Line Therapy in EGFR mutant NSCLC with Dr. Marcelo Corassa & Dr. Biagio Ricciuti (April 14, 2025)

In this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more. Join Us

Supportive Care & Telemedicine with Dr. Joseph McCollom & Dr. Cristiane Bergerot (March 26, 2025)

In this Interview Dr. McCollom & Dr. Bergerot discuss Telehealth. Dr. Bergerot, a psychologist and head of Supportive Care at Groupo Clinicas in Brazil dives into the critical role of TeleHealth in oncology and palliative care, focusing on how the COVID-19 pandemic accelerated the adoption of TeleHealth globally and its continued integration into healthcare systems, particularly for improving access to care in remote and underserved areas. 

Breast Cancer with Dr. Elisa Agostinetto & Dr. Maryam Lustberg Discussing Adj CDK4/6 inhibitors (March 14, 2025)

In this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer. Their discussion covers the use of Abemaciclib and Ribociclib following the monarchE and NATALEE trials, applications in the treatment of male breast cancer, and much more.

Prostate Cancer with Dr. Silke Gillessen & Dr.Aurelius Omlin of APCCC (March 5, 2025)

In this interview with Dr. Silke Gillessen and Dr. Aurelius Omlin, we delve into the origins and evolution of the Advanced Prostate Cancer Consensus Conference (APCCC), which began in 2015 to address critical questions in prostate cancer management where evidence is lacking or conflicting. Over the years, the conference has focused on various evolving topics, such as oligometastatic disease, treatment sequencing, and new imaging technologies. The 2024 APCCC highlighted major discussions on next-generation imaging, genomic biomarkers, and diagnostic challenges, with a strong emphasis on the need to balance cutting-edge technology with clinical practicality. Looking ahead to APCCC 2026, the event will continue to address key issues, including the risk of overtreatment, international disparities in imaging access, and the integration of comorbidities into treatment decision-making. With a welcoming atmosphere, APCCC invites healthcare professionals worldwide to engage in these important discussions and contribute to shaping the future of prostate cancer care.
Proudly powered by Weebly
  • Home
  • Who are we?
  • OncoAlert🚨Colloquium
  • 🎙️PODCAST
  • VJ OncoAlert Journal Club
  • Oncology📰Monthly
    • Lung Cancer
    • Breast Cancer
    • GU Cancers
  • Multidisciplinary Perspectives in Breast Cancer
  • ASCO 2025